A Roadmap to Nonhematopoietic Stem Cell-Based Therapeutics: From the Bench to the Clinic

ISBN-13: 9780128119204 / Angielski / Miękka / 2018 / 544 str.

Xiao-Dong Chen

Spis treści

Part 1 Principles and Concepts

1. What Can We Learn From This Book?

Travis J. Block, David D. Dean and Xiao-Dong Chen

2. Features of Mesenchymal Stem Cells

Stan Gronthos

3. Maintenance and Culture of  MSCs

Milos Marinkovic, David D. Dean and Xiao-Dong Chen

4. Manufacturing Mesenchymal Stromal Cell Banks

Jamie Hoover and Patrick J. Hanley

Part 2 Promises and Challenges of MSC-Based Therapies

5. Mesenchymal Stem Cell-Based Therapy of Osteoarthritis: Current Clinical Developments and Future Therapeutic Strategies

Maxime Ruiz, Marie Maumus, Christian Jorgensen and Daniele Noel

6. Mesenchymal Stem Cell Therapy in Graft Versus Host Disease

Shivaprasad Manjappa, Rizwan Romee and Armin Rashidi

7. Systemic Lupus Erythematosus

Dandan Wang and Lingyun Sun

8. Mesenchymal Stem Cell-Based Therapies for Repair and Regeneration of Skin Wounds

Shanmugasundaram Natesan, Randolph Stone, Rodney K. Chan and Robert J. Christy

9. Myocardial Infarction

Natalia Rozwadowska and Maciej Kurpisz

10. Bone Marrow Mesenchymal Stem Cells as a New Therapeutic Approach for Diabetes Mellitus

Joseph Kim, John Z. Q. Luo and Luguang Luo

11. Mesenchymal Stem Cell-Based Therapy for Chronic Kidney Disease

Maria V. Irazabal, LaTonya J. Hickson and Alfonso Eirin

12. Promises and Challenges of MSC-Based Therapies: Parkinson Disease and Parkinsonism

Ashley Aaroe and Claire Henchcliffe

13. Spinal Cord Injury

K. A. Ruppert, S. D. Olson and C. S. Cox

14. Stem Cell-Based Restoration of Salivary Gland Function

Olivia N. Tran, Hanzhou Wang, David D. Dean, Xiao-Dong Chen and Chih-Ko Yeh

15. Tooth and Dental Pulp Regeneration

Bei Li, Chen Xi and Yan Jin

Part 3: Future Perspectives

16. MSCs as Biological Drugs

Thekkeparambil Chandrabose Srijaya, Sandhya Sriram, Noor Hayaty Abu Kasim and Shigeki Sugii

17. Mesenchymal Stem Cell-Derived Products for Tissue Repair and Regeneration

Anand Srinivasan, Michelle Lynn Fults, Peter Supronowicz, Roberto Esquivel and Rogelio Zamilpa

18. Use of MSCs in Antiaging Strategies

Travis J. Block, David D. Dean and Xiao-Dong Chen

19. Regulatory Developments for Nonhematopoietic Stem Cell Therapeutics: Perspectives From the EU, the USA, Japan, China, India, Argentina, and Brazil

Achim Rosemann, Gabriela Bortz and Federico Vasen

O autorze

Xiao-Dong Chen, M.D., Ph.D. is currently a Professor in the Department of Comprehensive Dentistry and Chief of the Regenerative Medicine Program in the School of Dentistry at the University of Texas Health Science Center at San Antonio. He is also the founder and Chief Scientific Officer of StemBioSys, Inc., San Antonio, Texas and a Visiting Professor at Shanghai Jiao-Tong University School of Medicine.
Dr. Chen received his M.D. from Shanghai Jiao-Tong University School of Medicine, subsequently entered General Surgery residency, and then served as a staff General Surgeon. He also has a Ph.D. in Hematology and Developmental Immunology and has pursued the study of mesenchymal stem cells (MSCs) since 1993. He received post-doctoral training in stem cell and skeletal biology at Yale University and the National Institute of Dental and Craniofacial Research (NIDCR) in Bethesda, Maryland.
Dr Chen's group was the first to establish a culture system, using cell-free native ECM, for expanding large numbers of high-quality non-hematopoietic stem cells (NHSCs) from various sources. To closely replicate the tissue specific microenvironment (niche) ex vivo, Dr. Chen and his team have extended their technology and developed 3D tissue-specific matrices for use in a variety of stem cell-based applications such as: 1) rejuvenating NHSCs from the elderly to establish a personal stem cell bank containing large numbers of high-quality autologous cells for treating age-related diseases; 2) inducing NHSC differentiation into the salivary gland epithelial cell lineage for repairing damaged salivary gland; and 3) enhancing the efficacy of bone marrow-derived MSCs for treating community-acquired pneumonia. The cell culture technology has also been used for other applications such as preserving pancreatic islet function, while reducing islet immunogenicity, for use in islet transplantation to treat type 1 diabetes.
To foster the translation of his laboratory discoveries, Dr. Chen co-founded a startup company in 2010 (StemBioSys, Inc.; www.stembiosys.com). During the last several years, the company has been developing technology for scaling up the production of stem cells for treating human diseases, and providing a unique platform for quickly developing broad collaborations with other research institutes and biotech companies for basic research and clinical applications.